The EIF2AK1 Knockout HAP1 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal knockout population targeting the EIF2AK1 gene (encoding heme-regulated inhibitor kinase, HRI) in the human HAP1 cell line. This polyclonal knockout model is designed for loss-of-function studies of EIF2AK1 within the integrated stress response (ISR) pathway. As a polyclonal population, the cells represent a heterogeneous mixture of gene-disrupted alleles, providing a robust tool for investigating EIF2AK1-dependent signaling without the biases associated with single-cell clones.
The HAP1 cell line is a human chronic myeloid leukemia (CML)-derived near-haploid cell line with an adherent fibroblast-like morphology. Originating from KBM-7 cells, HAP1 cells stably maintain a near-haploid chromosomal complement, making them exceptionally suited for genetic screens and knockout studies due to simplified allele disruption. Their haploid genetic background minimizes the complexity of gene targeting, enabling efficient generation of complete gene disruptions ideal for functional genomic analyses.
EIF2AK1 encodes the heme-regulated inhibitor (HRI), a stress-responsive eIF2?? kinase activated by heme deficiency, oxidative stress, heat shock, or proteasome inhibition. Upon activation, HRI phosphorylates eIF2?? (EIF2S1), inhibiting eIF2B-mediated guanine nucleotide exchange and attenuating global translation while promoting selective translation of ATF4. ATF4 induces expression of stress-response genes including CHOP and GADD34, which complexes with PP1 to dephosphorylate eIF2??, providing feedback regulation. HRI is directly inhibited by heme binding and interacts with HSP90 and HSP70.
In the HAP1 background, disruption of EIF2AK1 eliminates HRI-mediated eIF2?? phosphorylation, rendering cells deficient in this specific arm of the ISR. Given HAP1’s near-haploid status, the knockout phenotype is unambiguous, permitting clear dissection of HRI-dependent signaling events without interference from residual wild-type alleles. This model is particularly valuable for exploring the role of HRI in erythroid differentiation and the pathophysiology of anemia, where heme-regulated translational control is critical. Moreover, it provides a platform for investigating how cancer cells, including leukemic blasts, subvert the ISR to survive metabolic and proteotoxic stress.
This knockout model facilitates detailed mechanistic studies of translational control and the ISR. Compatible assays include western blot analysis of phospho-eIF2?? and ATF4, RT-qPCR for ATF4, CHOP, and GADD34, ATF4-luciferase reporter assays, and flow cytometry for apoptosis. The cells are ideal for screening ISR modulators, investigating heme metabolism crosstalk, and evaluating EIF2AK1-targeted therapies in a leukemic context. For further information, please contact Ascent Research.
